For research use only. Not for therapeutic Use.
Blarcamesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1].
Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1].
Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1].
Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1].
Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1].
| Catalog Number | I003303 |
| CAS Number | 195615-83-9 |
| Synonyms | 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine |
| Molecular Formula | C19H23NO |
| Purity | ≥95% |
| InChI | InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3 |
| InChIKey | BOTHKNZTGGXFEQ-UHFFFAOYSA-N |
| SMILES | CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3 |
| Reference | [1]. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796. |
